Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) — Market Cap & Net Worth
Market Cap & Net Worth: Eloxx Pharmaceuticals, Inc. (ELOX)
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) has a market capitalization of $56.94 Million ($56.94 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21507 globally and #4825 in its home market, demonstrating a 21.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eloxx Pharmaceuticals, Inc.'s stock price $18.25 by its total outstanding shares 3436314 (3.44 Million). Also see Eloxx Pharmaceuticals, Inc. assets under control for a full breakdown of the balance sheet.
Eloxx Pharmaceuticals, Inc. Market Cap History: 2026 to 2026
Eloxx Pharmaceuticals, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $62.71 Million to $62.71 Million (0.00% CAGR). Also see Eloxx Pharmaceuticals, Inc. (ELOX) cash flow conversion for how efficiently the company converts equity into cash flow.
Eloxx Pharmaceuticals, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eloxx Pharmaceuticals, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ELOX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ELOX by Market Capitalization
Companies near Eloxx Pharmaceuticals, Inc. in the global market cap rankings as of September 17, 2026. Review Eloxx Pharmaceuticals, Inc. tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Eloxx Pharmaceuticals, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Eloxx Pharmaceuticals, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Eloxx Pharmaceuticals, Inc.'s market cap moved from $62.71 Million to $ 62.71 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $62.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Eloxx Pharmaceuticals, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $56.94 Million USD |
| MoneyControl | $56.94 Million USD |
| MarketWatch | $56.94 Million USD |
| marketcap.company | $56.94 Million USD |
| Reuters | $56.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more